XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder’s Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2021 $ 145,979 $ 228,084,195 $ (96,047,821) $ 132,182,353 $ 600,380 $ 132,782,733
Balance (in Shares) at Sep. 30, 2021   145,979,429          
Issuance of common stock for services $ 50 95,834 95,884 95,884
Issuance of common stock for services (in Shares)   50,201          
Stock-based compensation expense 904,604 904,604 904,604
Net loss (9,225,220) (9,225,220) (9,225,220)
Balance at Dec. 31, 2021 $ 146,029 229,084,633 (105,273,041) 123,957,621 600,380 124,558,001
Balance (in Shares) at Dec. 31, 2021   146,029,630          
Balance at Sep. 30, 2022 $ 146,211 232,368,121 (129,688,467) 102,825,865 600,380 103,426,245
Balance (in Shares) at Sep. 30, 2022   146,211,130          
Stock-based compensation expense 1,201,081 1,201,081 1,201,081
Net loss (3,593,645) (3,593,645) (3,593,645)
Balance at Dec. 31, 2022 $ 146,211 $ 233,569,202 $ (133,282,112) $ 100,433,301 $ 600,380 $ 101,033,681
Balance (in Shares) at Dec. 31, 2022   146,211,130